Ambroxol
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ambroxol: From Mucolytic Agent to Nasal Cavity Disease
One-Sentence Summary
Ambroxol is a well-established mucolytic and secretolytic agent widely used across respiratory tract conditions to promote mucus clearance and improve airway drainage. The TxGNN model predicts it may be effective for Nasal Cavity Disease, with 0 clinical trials and 1 publication currently supporting this specific direction. Evidence for this particular repurposing application remains at an early exploratory stage, warranting further investigation before clinical consideration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Respiratory tract conditions with excessive or viscous mucus (mucolytic/secretolytic use) |
| Predicted New Indication | Nasal Cavity Disease |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L4 |
| Singapore Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from the Evidence Pack. Based on known pharmacological knowledge, Ambroxol is a mucoactive compound — a metabolite of bromhexine — that stimulates production of serous bronchial secretions, activates mucociliary clearance, and normalises abnormal mucus rheology. It also exhibits anti-inflammatory properties through inhibition of pro-inflammatory mediator release, as well as local anaesthetic effects via blockade of voltage-gated sodium channels (Nav1.7 and Nav1.8).
The connection between Ambroxol and nasal cavity disease is mechanistically plausible. The nasal mucosa relies on the same mucociliary transport mechanisms that Ambroxol enhances in the lower airway. Excessive or abnormally viscous nasal secretions are a cardinal feature of rhinitis, sinusitis, and upper respiratory tract infections — all conditions within the "nasal cavity disease" spectrum. Ambroxol's ability to normalise mucus secretion and reduce hypersecretion of mucins could improve nasal mucosal clearance function. Additionally, its sodium channel blocking action may attenuate the sensation of nasal congestion via an indirect sensory mechanism.
However, it is important to note that the available Evidence Pack contains only one supporting publication (a review commentary on acute cough), and no registered clinical trials for this specific indication were identified. The prediction therefore primarily reflects a mechanistic inference captured by the knowledge graph rather than established clinical data. This limits the interpretability of the TxGNN score and the decision should be treated as a research hypothesis rather than a validated repurposing candidate.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 26525480 | 2015 | Review/Commentary | Vestnik otorinolaringologii | Discusses acute cough associated with influenza and ARVI; notes that ARVI-related cough is typically non-productive and resolves within 2–3 weeks, with some cases producing abnormal sputum — context relevant to upper respiratory mucosal conditions including nasal involvement |
Singapore Market Information
Ambroxol is currently not marketed in Singapore. No HSA product authorisations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Although the TxGNN prediction score is high (99.91%) and the mechanistic hypothesis is biologically coherent, no clinical trials and only one indirect literature reference were identified for Ambroxol in nasal cavity disease specifically. The evidence grade of L4 is insufficient to support a repurposing recommendation at this time; the prediction is best characterised as a research question.
To proceed, the following is needed:
- Retrieve full MOA data from DrugBank (DB06742) to strengthen the mechanistic rationale
- Conduct a targeted PubMed search for Ambroxol combined with rhinitis, sinusitis, or nasal congestion to identify any overlooked publications
- Search ClinicalTrials.gov and ICTRP using broader upper respiratory tract terms to identify relevant trials not captured under "nasal cavity disease"
- Review HSA records for any off-label or compassionate use precedents of Ambroxol in Singapore
- Retrieve TFDA or EMA product insert safety warnings and contraindications to complete the safety profile (currently Data Gap)
- If mechanistic and safety gaps are resolved, consider designing a Phase 2 pilot study or prospective observational cohort to generate L2–L3 level evidence
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.